What is Third Pole Therapeutics?
Third Pole Therapeutics operates at the intersection of advanced engineering and pulmonary medicine. The company specializes in the development of portable and wearable devices designed for the precise delivery of inhaled nitric oxide. By focusing on miniaturization and accessibility, Third Pole Therapeutics addresses the historical limitations of hospital-bound respiratory therapies. Their market position is defined by a commitment to clinical rigor and the transformation of life-saving gas delivery systems into mobile, user-friendly platforms that serve both healthcare providers and patients in diverse clinical environments.
How much funding has Third Pole Therapeutics raised?
Third Pole Therapeutics has raised a total of $39.1M across 3 funding rounds:
Unspecified
$13.8M
Debt
$350K
Unspecified
$25M
Unspecified (2015): $13.8M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Unspecified (2022): $25M, investors not publicly disclosed
Key Investors in Third Pole Therapeutics
PPP
Public-Private Partnership
Undisclosed Investor
An institutional backer participating in the latest round to support the scaling of respiratory therapeutic innovations.
Undisclosed Investor
A strategic partner providing capital to facilitate the transition of clinical-stage medical devices into commercial markets.
What's next for Third Pole Therapeutics?
With the recent influx of capital, Third Pole Therapeutics is well-positioned to accelerate its clinical trial pipeline and expand its manufacturing capabilities. The strategic focus will likely shift toward regulatory milestones and the commercial scaling of its wearable nitric oxide delivery systems. As the company moves deeper into its growth phase, the integration of these devices into standard-of-care protocols will be critical. Investors and industry stakeholders are closely monitoring the firm's ability to navigate the complex regulatory landscape while maintaining the technological edge that distinguishes its therapeutic portfolio in the global respiratory market.
See full Third Pole Therapeutics company page
